Levi & Korsinsky Urges PROCEPT BioRobotics Corporation (PRCT) Shareholders to Act Before Lead Plaintiff Deadline September 22, 2026
NEW YORK CITY, NY / ACCESS Newswire / July 29, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired PROCEPT BioRobotics Corporation (NASDAQ:PRCT) securities.
If you suffered a loss on your PROCEPT BioRobotics Corporation investment and would like to explore a potential recovery under the federal securities laws, Learn about PROCEPT BioRobotics Corporation Class Action or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: A class action securities lawsuit was filed against PROCEPT BioRobotics Corporation that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2026.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) during the class period, Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (b) Procept's undisclosed discount program had artificially and unsustainably inflated the Company's reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (c) Procept's undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the class period and that this differential had materially grown over time; (d) Procept's consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept's customer base, amounting to more than 10,000 excess units by the end of the Class Period; (e) as a result of (a)-(d) above, defendants' representations during the class period regarding Procept's handpiece unit sales and the utilization of Procept's field Systems were materially overstated; (f) as a result of (a)-(e) above, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (g) as a result of (a)-(f) above, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.
WHAT'S NEXT? If you purchased PROCEPT BioRobotics Corporation stock during the relevant time frame - even if you still hold your shares, learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP